Corporate News

Acrivon Therapeutics (ACRV) experienced a notable uptick in share price during a 24‑hour trading window that concluded at 04:27 PM Central Europe on Wednesday, 21 October 2026. The stock closed up 6.21 %, settling at approximately USD 1.84 on major exchanges. With a circulating supply of 42.9 million shares, the company’s market capitalization currently stands at USD 72.4 million. In the past 24 hours, trading volume amounted to roughly USD 332.1 k.

The recent performance is part of a broader trend, as Acrivon’s shares have fallen 10.7 % since the end of September. The 200‑day simple moving average sits at USD 1.78, and the 52‑week high (USD 3.56) and low (USD 1.27) were recorded on 01 July 2026 and 30 March 2026 respectively.

Contextual Market Movements

Acrivon’s peers have shown mixed results in the same timeframe:

  • Sono‑tek (SOTK) – Down 3.47 %, now trading at USD 5.24 with a market cap of USD 86.2 million. The company’s price‑to‑earnings ratio is 45.83.
  • Aib Data Centers (AIB) – Up 1.75 %, trading at USD 1.12 with a market cap of USD 86.6 million. AIB disclosed an investor presentation on 20 October 2026 that outlines its strategy for right‑sized data‑center facilities aimed at AI and high‑performance computing customers, emphasizing a phased construction model that secures utility power before capital commitments. The filing also contains forward‑looking statements regarding projected performance, financing, and regulatory approvals.
  • Corbus Holdi (CRBP) – Down 0.9 %, trading at USD 4.48 with a market cap of USD 86.3 million.
  • Rallybio (RLYB) – Up 0.18 %, trading at USD 16.37 with a market cap of USD 86.8 million and a price/earnings ratio of 2.04. The company reported two Form 4 filings on 20 October 2026 that detail share acquisitions by directors Soteropoulos Paula and Helen Boudreau, both under the 2021 Equity Incentive Plan.
  • Ebr (EBR.AX) – Up 3.45 %, trading at AUD 0.14 with a market cap of AUD 122.6 million. EBR Systems Inc highlighted progress on its WiSE® System, noting a submitted TGA ARTG application and a U.S. FDA approval milestone, which contributed to a modest share price increase.

Company Overview

Acrivon Therapeutics, Inc. is a clinical‑stage oncology firm headquartered in Watertown, United States. The company focuses on predictive precision proteomics technology that enables the development of drug‑tailored companion diagnostics. By linking drug mechanisms to active disease‑driving processes in cancer patients, Acrivon’s platform seeks to uncover drug sensitivity beyond the capabilities of traditional genomics analysis. The company is listed on the Nasdaq stock exchange and completed its initial public offering on 10 November 2022.

This blend of technological innovation and recent market activity positions Acrivon as a noteworthy player within the oncology diagnostics sector, with its stock performance reflecting both the challenges of clinical development and the optimism of investors in precision medicine breakthroughs.